Brand Institute’s Post

Congratulations to life sciences industry veterans Mario Philips, Roel Gordijn, and the entire Healthcare Team at Warburg Pincus on the launch of Enovo Life Sciences! #BIbrands Enovo Life Sciences is an institutionally capitalized platform dedicated to partnering with innovative businesses in the biologics and advanced therapies markets. Backed by Warburg Pincus, a leading global growth investor, Enovo Life Sciences will provide companies with capital, deep sector expertise, and access to a global network to drive innovation and address the evolving needs of customers and patients worldwide. As the global leader in pharmaceutical and healthcare-related brand name and identity development, Brand Institute is proud to have partnered with Enovo Life Sciences in creating their new corporate brand name! #naming #branding #healthcare #corporateidentity

We're excited to share that Nakos Balamotis, President of EU Regulatory Affairs for Drug Safety Institute, a wholly-owned subsidiary of Brand Institute, will be attending the World Drug Safety Congress Europe 2024 in Amsterdam on October 9th and 10th. Drug safety is critical to our mission, which is why we established Drug Safety Institute, focused on providing regulatory expertise that not only ensures the highest standards in patient safety but also offers our clients greater predictability and confidence throughout the regulatory review process. If you're attending the World Drug Safety Congress, Nakos would love to connect! Feel free to direct message him or you can reach him at: Email: ibalamotis@brandinstitute.com Mobile: +44(0) 779-258-1486 #DrugSafety #RegulatoryAffairs #WorldDrugSafetyCongress #PatientSafety

Greetings from the Fierce Biotech Summit in Boston, MA! Brand Institute's Boston-based team, Daina Quevedo, PharmD and Connor Davey, PharmD, are here at Booth #31, ready to chat about Brand Institute's services and how we can help biotech companies develop winning brand names and identities. #naming #branding #biotech #conferences

Congratulations to Bristol Myers Squibb on the FDA approval of COBENFY™ (xanomeline and trospium chloride) for the treatment of schizophrenia in adults. #BIbrands COBENFY is a first-in-class muscarinic agonist and represents the first new pharmacological approach to treating schizophrenia in decades. #naming #branding #FDAapproval #schizophrenia

Brand Institute is pleased to announce that we are attending BIO-Europe in Stockholm, Sweden this November 4-6, 2024. Two of our Divisional Presidents, Steffen Lorenz and Mark Ghobry, look forward to meeting and connecting with thought leaders from the global life science community. See you at booth #30! EBD Group #conferences #lifesciences

Congratulations to Elanco on the FDA approval of Zenrelia (ilunocitinib tablets)! #BIbrands Zenrelia is a new animal health product used to control pruritus (itching) associated with allergic dermatitis and to control atopic dermatitis (environmental allergies) in dogs at least 1 year of age. It is an orally-administered, once daily, non-selective Janus kinase (JAK) inhibitor. #Naming #Branding #FDAapproval #AnimalHealth #Veterinary

Congratulations to Genentech, a member of the Roche Group, on the FDA approval of Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs), the first and only subcutaneous anti-PD-(L)1 cancer immunotherapy. #BIbrands Subcutaneous Tecentriq Hybreza will provide patients and physicians with greater flexibility of treatment options and reduce treatment time compared to IV infusion, while showing safety and efficacy consistent with intravenous Tecentriq. Tecentriq Hybreza will be available for all IV indications of Tecentriq approved for adults in the U.S., including certain types of lung, liver, skin and soft tissue cancer. #branding #naming #FDAapproval #oncology

Congratulations to Bayer and Regeneron on the European Medicines Agency (EMA) approval of OcuClick, a pre-filled syringe for the administration of Eylea 8 mg. #BIbrands The new OcuClick pre-filled syringe will provide ophthalmologists with an efficient and simple way to accurately deliver the 70-microliter dose of Eylea 8 mg for the approved indications of neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME). Germany will be one of the first markets where the pre-filled syringe is launched. #naming #branding #EMAapproval #AMD #innovation #drugdelivery #medicaldevice

Congratulations to Johnson & Johnson Innovative Medicine on the EMA approval of Balversa (erdafitinib)! #BIbrands Balversa is a a once-daily, oral, FGFR3-alteration-targeting monotherapy indicated for the treatment of adult patients with unresectable or metastatic urothelial carcinoma (mUC). #naming #branding #EMAapproval #BladderCancer

Congratulations to Incyte and Syndax on the FDA approval of Niktimvo (axatilimab-csfr)! #BIbrands Niktimvo is a novel anti-CSF-1R antibody approved for the treatment of chronic graft-versus-host disease (GVHD). #naming #branding #FDAapproval #GVHD